GraphiteRx
GraphiteRx operates a cloud-native, AI-powered B2B pharmaceutical commerce platform that consolidates non-wholesaler drug procurement, 340B compliance, and supplier e-commerce for hospitals, pharmacies, and manufacturers. It serves 1,000+ providers and powers white-label marketplaces including Cost Plus Drugs.
- Company typePrivate
- Founded2018
- HeadquartersNashville, United States
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What GraphiteRx does
GraphiteRx is a U.S.-based healthcare commerce platform founded in 2018 and headquartered in Nashville, Tennessee, that operates a cloud-native, AI-powered B2B pharmaceutical commerce platform consolidating direct (non-wholesaler) drug procurement for hospitals, pharmacies, and clinics. The company addresses fragmented purchasing workflows, 340B compliance exposure, drug-shortage access, and supplier-side distribution costs that traditional three-wholesaler channels leave unsolved, particularly for smaller manufacturers and providers.
The platform is delivered through three integrated products: GraphiteOM, an all-in-one procurement and 340B compliance platform for health system pharmacies; ePortal, a pharma-specific e-commerce solution for manufacturers, distributors, and 503B outsourcers featuring DEA-certified CSOS, DSCSA traceability, automated license verification, and contract-specific pricing; and Marketplace Solutions, a turnkey 'marketplace in a box' that enables healthcare innovators and trade groups to launch co-branded B2B pharma marketplaces in weeks. The underlying technology includes an EDI hub processing standard transaction sets (832/850/855/856/810), AI-driven order management with anomaly detection, and an invoice-agent model that underwrites buyer credit risk and guarantees supplier payment regardless of buyer payment behavior.
GraphiteRx monetizes through marketplace and platform transaction fees on more than $500M in annual purchasing volume across 1,000+ provider organizations, managed-services revenue from credit-risk underwriting, and licensing/operational fees from white-label co-branded deployments, the most prominent being its Mark Cuban Cost Plus Drugs partnership that serves over 40 million patients annually. The company employs 11–50 staff, runs an enterprise field-sales motion targeting pharmacy and 340B leaders with first-year quotas near $1M ARR per rep, and supplements direct sales with GPO, trade-group, and healthcare-innovator partner channels.
GraphiteRx firmographics
Firmographics- Name
- GraphiteRx
- Legal name
- GraphiteRx Inc.
- Website
- https://graphiterx.com
- Company type
- Private
- Founded year
- 2018
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- GraphiteRx operates a cloud-native, AI-powered B2B pharmaceutical commerce platform that consolidates non-wholesaler drug procurement, 340B compliance, and supplier e-commerce for hospitals, pharmacies, and manufacturers. It serves 1,000+ providers and powers white-label marketplaces including Cost Plus Drugs.
- Ownership category
- akta.pro rank
GraphiteRx industry classification
Industry- Product category
- Pharmaceutical Commerce Platform
- NAICS
- Drugs and Druggists' Sundries Merchant Wholesalers (42421), Drugs and Druggists' Sundries Merchant Wholesalers (424210), Drugs and Druggists' Sundries Merchant Wholesalers (4242), Pharmacy Benefit Management and Other Third Party Administration of Insurance and Pension Funds (524292)
- SIC
- Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
- akta.pro primary industry
- B2B Marketplaces & Wholesale Platforms (BPAMAGAD)
- akta.pro secondary industries
- 340B Program Administration & Contract Pharmacy Services (HLAFALAL), Pharmacy Benefit/Channel Services (PSAO, 340B Admin, Chargebacks/Rebates Ops) (CRAOAHAK), Invoicing, Billing & Accounts Receivable Automation (FSAGAJAC), B2B / Invoice-Based BNPL (Trade Credit at Checkout) (FSAGAIAC)
Keywords
Where GraphiteRx is headquartered
LocationHeadquarters
- HQ city
- Nashville
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
GraphiteRx business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure
Revenue model
- Marketplace Transaction Fees / Platform Fees: GraphiteRx operates a B2B pharmaceutical marketplace and earns revenue by facilitating transactions between buyers (hospitals, pharmacies, clinics) and suppliers (manufacturers, distributors). GraphiteRx acts as invoice agent, managing AR and credit risk, with pricing on open-market/WAC accounts with no markup or discount to supplier pricing.
- Supplier Payment Guarantee (B2B Marketplace): GraphiteRx guarantees supplier payment for undisputed invoices regardless of customer payment timing. This credit risk underwriting function represents a revenue-generating service for suppliers, with GraphiteRx absorbing buyer credit risk in exchange for fees or spread.
- White-Label / Co-Branded Marketplace Licensing: Partners (healthcare innovators, trade groups) pay for turnkey 'marketplace in a box' solutions — receiving a white-labeled, branded B2B pharma marketplace powered by GraphiteRx. Revenue generated from platform fees, transaction processing, and operational management services.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Annual | Platform pricing is not publicly disclosed; all engagement is quote-based. |
Go-to-market motion2 records
Distribution channels4 records
Marketing channels4 records
GraphiteRx product offering
Product offeringCore offering
GraphiteRx operates a cloud-based B2B healthcare commerce platform that consolidates direct (non-wholesaler) pharmaceutical procurement onto a single AI-driven system. Its portfolio—GraphiteOM for provider procurement and 340B compliance, ePortal for supplier e-commerce with built-in CSOS/DSCSA/license verification, and turnkey Marketplace Solutions—unifies ordering, compliance, EDI integration, and supplier-payment guarantees. The platform powers white-label B2B pharma marketplaces, including the Cost Plus Drugs Marketplace for Businesses, serving over 1,000 hospitals, pharmacies, and clinics managing $500M+ in annual purchasing.
Product overview
GraphiteRx operates as a healthcare commerce platform delivering AI-driven technology for pharmaceutical procurement, compliance, and marketplace solutions. The portfolio consists of three core integrated solutions: GraphiteOM (provider-facing procurement and 340B compliance platform), ePortal (supplier-facing pharma e-commerce solution), and Marketplace Solutions (turnkey B2B marketplace infrastructure). These products share a unified technology foundation with built-in compliance (340B, DSCSA, CSOS, license verification), EDI integration capabilities, and shared marketplace infrastructure, enabling seamless transactions across providers, suppliers, and marketplace operators including white-label partnerships like Cost Plus Drugs.
Differentiator
Problem solved
Functional benefit
Brands
- GraphiteOM: AI-powered all-in-one platform for health system pharmacies to manage 340B compliance and pharmacy procurement, including split-billing, audit readiness, and account validation.
- ePortal
Products and services
- GraphiteOM All-in-one AI-powered platform for health system pharmacies, hospitals, and clinics to manage non-primary wholesaler purchasing, 340B compliance, split-billing, accumulation reporting, and audit readiness through a centralized procurement interface.
- ePortal (GraphiteRx eCommerce Solution) Pharma-specific e-commerce platform for manufacturers, distributors, and 503B outsourcing facilities, providing a branded online ordering experience with built-in compliance (CSOS, license verification), contract-specific pricing, and EDI/API integration to ERP or 3PL fulfillment systems.
- Marketplace Solutions Turnkey co-branded B2B pharmaceutical marketplace offering for healthcare innovators, trade groups, and partner organizations, bundling technology, compliance, payments, and operations into a 'marketplace in a box' that partners can white-label and launch in weeks.
- Graphite Marketplace B2B pharmaceutical marketplace connecting hospitals, pharmacies, and clinics with manufacturers and authorized distributors for drug shortage products, specialty items, biosimilars, vaccines, and medical devices, with order-to-cash, compliance, and payment processing handled on platform.
- Cost Plus Drugs Marketplace for Businesses Co-branded B2B pharmaceutical marketplace powered by GraphiteRx for Mark Cuban Cost Plus Drugs, enabling healthcare providers to purchase lower-cost medications through a transparent, compliant ordering platform with GraphiteRx handling onboarding, EDI, fulfillment coordination, and payments.
Quantifiable outcome
- Over $500M in purchasing managed through the platform annually
- +3 more outcomes
Companies that use GraphiteRx
Customer profileNamed customers3 records
Segments3 records
Ideal customer profiles3 records
GraphiteRx technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration4 records
AI capability3 records
Feature8 records
GraphiteRx partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core.
- Mark Cuban Cost Plus DrugscoreGraphiteRx provides the technology infrastructure powering the Cost Plus Drugs Marketplace for Businesses. This includes customer onboarding, supplier management, EDI integrations, order processing, fulfillment coordination, payment processing, and customer support. Cost Plus Drugs focuses on its core mission of expanding access to affordable medications through transparency. The partnership was deepened in December 2025 and serves over 40 million patients annually.
- Group Purchasing Organizations (GPOs)coreGraphiteRx partners with GPOs and organizations that help providers manage spend. The partnership ensures hospitals, pharmacies, and clinics can reduce costs and access products through a unified marketplace. GPO-affiliated pricing and class-of-trade pricing are supported on the platform.
- Pharmaceutical Manufacturers and DistributorscoreGraphiteRx partners with manufacturers, distributors, and 503B outsourcing facilities to enable direct-to-pharmacy distribution through the Graphite Marketplace. Suppliers gain access to over 1K hospitals, pharmacies, and clinics managing $500M+ in purchasing, with full control over catalog and pricing, and guaranteed payment.
Scale indicators4 records
Recent moves6 records
Expansion highlights6 records
GraphiteRx competitors and assessment
Company assessmentEmerging players
- Capital Rx: Capital Rx is a next-generation PBM operating a transparent, technology-driven pharmacy benefit platform (Judi Health). Comparable to GraphiteRx in its mission to disrupt legacy pharma intermediaries with modern technology and transparent pricing.
- BluePallet: BluePallet operates a B2B commerce and payments platform for the chemical and life sciences industry, with similar marketplace infrastructure (compliance, payments, EDI). Comparable to GraphiteRx's marketplace-in-a-box model applied to specialty inputs.
- RxBenefits: RxBenefits is a pharmacy benefits optimizer serving self-funded employers with PBM contracting, specialty drug procurement, and 340B advisory. Adjacent to GraphiteRx in its mission to lower drug costs through non-traditional procurement channels.
Broad incumbents
- McKesson: McKesson is the largest U.S. pharmaceutical wholesaler and operates extensive 340B services (including Macro Helix/RxO). It is a broad incumbent that competes with GraphiteRx across primary and non-primary wholesale distribution, 340B administration, and digital procurement.
- Cardinal Health: Cardinal Health is a top-three U.S. pharma distributor with a large hospital and ambulatory pharmacy footprint (including its OutcomesMTM and specialty businesses). Comparable to GraphiteRx across direct and non-primary wholesale distribution.
- Cencora (AmerisourceBergen): Cencora is the #2 U.S. pharma wholesaler with deep GPO relationships (Walgreens Boots Alliance Development, ClarusONE) and growing specialty/340B capabilities. Comparable to GraphiteRx in the wholesale and 340B channel-services arena, but at massive scale.
Direct peers
- Mark Cuban Cost Plus Drug Company: Cost Plus Drugs is GraphiteRx's flagship white-label partner and direct-to-consumer pharma disruptor. The Cost Plus Marketplace for Businesses is powered by GraphiteRx, so the two operate in tightly intertwined channels across DTC affordability and B2B procurement.
- CaptureRx: CaptureRx is a 340B contract pharmacy administrator and technology provider for hospitals and health systems. Direct overlap with GraphiteRx's 340B split-billing and contract pharmacy services for covered entities.
- Macro Helix (McKesson): Macro Helix is a leading 340B program administration and split-billing platform serving covered entities. It is a direct competitor to GraphiteRx's GraphiteOM 340B compliance and accumulation-reporting functionality.
- Sentry Data Systems (Cencora/World Courier): Sentry Data Systems provides 340B software, split-billing, and contract pharmacy administration to hospitals and FQHCs. Closely comparable to GraphiteOM's 340B compliance, audit-readiness, and account-validation workflows.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
GraphiteRx social profiles
Digital presenceGraphiteRx compliance and trust
Trust signalCompliance1 record
GraphiteRx financial estimates
Financial estimateRevenue estimate
Valuation estimate
GraphiteRx leadership team
Management profileNumber of profiles
Profiles3 records
GraphiteRx funding detail
Funding detailFunding overview
Funding rounds1 record
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
GraphiteRx M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about GraphiteRx
What does GraphiteRx do?
GraphiteRx operates a cloud-based B2B healthcare commerce platform that consolidates direct (non-wholesaler) pharmaceutical procurement onto a single AI-driven system. Its portfolio—GraphiteOM for provider procurement and 340B compliance, ePortal for supplier e-commerce with built-in CSOS/DSCSA/license verification, and turnkey Marketplace Solutions—unifies ordering, compliance, EDI integration, and supplier-payment guarantees. The platform powers white-label B2B pharma marketplaces, including the Cost Plus Drugs Marketplace for Businesses, serving over 1,000 hospitals, pharmacies, and clinics managing $500M+ in annual purchasing.
Is GraphiteRx a public or private company?
GraphiteRx is a private company. It is classified as venture growth investor backed and is currently operating.
When was GraphiteRx founded?
GraphiteRx was founded in 2018. It employs 11 to 50 people.
Where is GraphiteRx based?
GraphiteRx is headquartered in Nashville, United States, in the North America region.
How does GraphiteRx make money?
Three revenue lines are on record. Marketplace Transaction Fees / Platform Fees are the primary driver. The others are supplier Payment Guarantee (B2B Marketplace) and white-Label / Co-Branded Marketplace Licensing.
Who are GraphiteRx's main competitors?
Emerging players on record are Capital Rx, BluePallet and RxBenefits. Broad incumbents are McKesson, Cardinal Health and Cencora (AmerisourceBergen). Direct peers are Mark Cuban Cost Plus Drug Company, CaptureRx, Macro Helix (McKesson) and Sentry Data Systems (Cencora/World Courier).
Does GraphiteRx have an API?
No public API is recorded for GraphiteRx.
What industry is GraphiteRx in?
GraphiteRx's product category is Pharmaceutical Commerce Platform. Its primary akta.pro industry code is BPAMAGAD, B2B Marketplaces & Wholesale Platforms, with a secondary code of HLAFALAL, 340B Program Administration & Contract Pharmacy Services. Its NAICS code is 42421 and its SIC code is 5122.